4-Methoxytriphenylchloromethane CAS 14470-28-1

Well‑known in biochemical research, MMT‑Cl is widely adopted as a protecting‑group reagent for selective protection of primary hydroxyl groups. This capability is vital for synthesizing complex molecules, as it temporarily shields target hydroxyl groups and avoids unwanted side reactions throughout synthetic workflows.

Beyond its synthetic utility, MMT‑Cl possesses promising pharmacological features that render it a prospective candidate for future drug development. While comprehensive pharmacological investigations remain in progress, preliminary findings indicate its interactions with biological systems may open doors to therapeutic uses.

In liquid‑phase and gas chromatography, 4‑methoxytriphenylmethane may be incorporated into the stationary phase. Its distinctive chemical properties, including polarity, hydrophobicity and hydrogen‑bonding potential, enable interactions with analytes and thereby enhance separation efficiency. Such interactions are governed by factors such as polarity, hydrophobicity and hydrogen‑bond formation. For instance, it helps resolve closely‑related aromatic isomer mixtures during fine‑chemical purification, improving peak shape and reducing peak tailing for non‑polar and moderately‑polar analytes.

For spectral analysis, 4‑methoxytriphenylmethane functions as a probe molecule for studying the spectral behaviour and molecular structure of other substances. It forms complexes or engages in intermolecular interactions with test compounds. Observed shifts in spectral characteristics allow researchers to deduce structural information and inherent properties of the analyte. It is frequently applied to investigate weak intermolecular forces such as hydroxyl‑π interactions within organic molecular systems via UV‑Vis and NMR spectrum variation tracking.

Entecavir belongs to the class of deoxyguanosine nucleoside analogues. It exerts its antiviral activity by inhibiting the HBV DNA polymerase, thereby blocking primer extension and chain elongation. This mechanism of action makes it highly effective in suppressing HBV replication. Notably, Entecavir has demonstrated superiority over Lamivudine, another antiviral agent, by being effective against Lamivudine-resistant HBV strains and exhibiting 30 times greater potency.

The active form of Entecavir, its triphosphate derivative, has a long intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine triphosphate for the HBV polymerase.

Approved by the former State Food and Drug Administration (SFDA, now NMPA) of China for treating patients with chronic hepatitis B, entecavir employs 4‑methoxytriphenylchloromethane as one of its key synthetic intermediates. Like all pharmaceutical agents, entecavir is associated with certain adverse events. Common treatment‑related reactions include headache, dizziness, fatigue, nausea and abdominal discomfort; these symptoms are generally mild‑to‑moderate in severity and tend to subside as therapy continues. Though uncommon, more serious adverse outcomes such as lactic acidosis and renal dysfunction require close clinical monitoring, particularly among patients suffering from advanced liver disease.

The main use is as a hydroxyl protecting reagent. In organic synthesis, many reactions require the presence of specific functional groups, and hydroxyl (- OH) groups, due to their high reactivity, often need to be protected during the reaction process to prevent them from participating in unnecessary side reactions. By undergoing dechlorination and etherification reaction with hydroxyl groups, stable ether bonds are formed to protect the hydroxyl groups. This protection method has the advantages of easy operation, mild reaction conditions, and easy removal of protective groups.Specifically, the protection of hydroxyl groups is crucial in complex organic synthesis processes such as peptide synthesis and nucleoside synthesis.

It also plays an important role in the field of pharmaceutical and chemical engineering, and is often used as a key raw material for synthesizing other drugs or pharmaceutical intermediates. For example, entecavir is one of the indispensable intermediates in the synthesis of anti hepatitis B virus drug. Entecavir is a cyclic valeryl guanosine analogue, which has a strong inhibitory effect on hepatitis B virus. The synthesis process involves multiple complex chemical reaction steps, among which the introduction of 4-methoxytriphenylchloromethane is crucial for constructing specific molecular structures.

In the specific synthesis steps, the precursor molecule of entecavir is gradually constructed by reacting with other compounds under specific conditions.

It also shows promising application value within materials science. Owning multiple benzene‑ring units in its molecular skeleton, it delivers favorable fluorescence performance. Incorporating 4‑methoxytriphenylchloromethane into target organic molecular structures can effectively improve the fluorescence behaviour of parent molecules, opening potential routes toward fluorescent labelling and fluorescent sensor development.For fluorescent labelling, it is capable of conjugating with biomolecules including proteins and nucleic acids to form fluorescent tags. Such tags support biomolecule detection and tracing, offering powerful tools for biomedical research.For cell‑imaging workflows, biomolecules modified with this labelling agent enable visual observation of specific intracellular components,

As a fine‑chemical intermediate with unique acid‑labile protecting‑group properties, 4‑methoxytriphenylchloromethane (MMT‑Cl) holds promising development potential across pharmaceutical synthesis, biomolecular research, analytical chemistry and functional‑materials fields.Driven by the rapid expansion of peptide, oligonucleotide and nucleoside‑derived drug research, demand for selective orthogonal protection reagents keeps rising. Distinguished by its moderate acid‑sensitivity, MMT‑Cl fills the technical gap between trityl chloride and DMT‑Cl. It performs well in selective shielding of primary amines and hydroxyl groups for complex multi‑step synthesis, especially suited for peptide solid‑phase synthesis and modified‑nucleoside preparation where finely‑tuned deprotection conditions are required.

Performance deviations caused by hydrolysis‑related impurities remain a key pain point for laboratory and industrial users. Future development will focus on optimizing purification processes, lowering hydrolytic impurities and stabilizing batch‑to‑batch consistency. Meanwhile, customized‑grade products for special scenarios will become an important development direction.Looking ahead, academic institutions and pharmaceutical enterprises will continue to dig into its new reaction modes and derivative applications. While it will not replace mainstream protecting‑group reagents, MMT‑Cl will maintain irreplaceable value in specific orthogonal‑protection workflows and emerging material‑exploration projects.